Sunday, February 15, 2026 2/15/2026

Antigen discovery for transmission-blocking vaccines in Plasmodium vivax

Award Number: R01AI150533
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/06/2020
PERIOD OF PERFORMANCE END DATE: 02/28/2025

Group Awards By:

View Award Description

Antigen discovery for transmission-blocking vaccines in Plasmodium vivax - Project Summary For the immense undertaking by many malaria-endemic nations to eliminate malaria, interruption of malaria transmission has been recognized as one of the greatest challenges, which requires integrated approaches. Plasmodium vivax, the most geographically widespread human malaria, is more resilient to conventional malaria control measures due to its intrinsic biology such as hypnozoite formation responsible for relapses and earlier gametocyte development enabling transmission before manifestation of symptoms. Transmission- blocking vaccines (TBVs) are a promising strategy especially suited for the task of elimination of vivax malaria. However, the progress in TBV development has been very slow, whereas TBV research for P. vivax lags even far behind that for Plasmodium falciparum. With only five parasite antigens as the top TBV candidates, concerted efforts to identify new TBV antigens are urgently needed. In this application, we propose to use an innovative antigen discovery pathway taking advantage of new protein expression and immunoscreening technologies, and advancement in vaccine design and delivery platforms. We aim to 1) discover new sexual- stage antigens by in silico prediction and immunoscreening, and evaluate their transmission reducing activities in Plasmodium berghei; 2) evaluate a TBV combination strategy targeting both pre- and post-fertilization antigens; and 3) assess the transmission reducing activities of new TBV candidates for P. vivax using transgenic P. berghei and clinical P. vivax isolates. Results from these comprehensive studies will contribute to a better understanding of sexual development in malaria parasites and identification of new sexual-stage antigens for the TBV development pipeline.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	CHINA MEDICAL UNIVERSITY	NO.77, PUHE RD., SHENBEI NEW AREA	SHENYANG				CHN	Allergy and Infectious Diseases Research	000	5	3/6/2025	TERMINATION	$0
2025	2024	CHINA MEDICAL UNIVERSITY	NO.77, PUHE RD., SHENBEI NEW AREA	SHENYANG				CHN	Allergy and Infectious Diseases Research	001	5	7/22/2025	TERMINATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $135,000 )
2024	2024	CHINA MEDICAL UNIVERSITY	NO.77, PUHE RD., SHENBEI NEW AREA	SHENYANG				CHN	Allergy and Infectious Diseases Research	000	5	6/21/2024	NON-COMPETING CONTINUATION	$135,000
														Subtotal = $135,000

Issue Date FY: 2023 ( Subtotal = $135,000 )
2023	2023	CHINA MEDICAL UNIVERSITY	NO.77, PUHE RD., SHENBEI NEW AREA	SHENYANG				CHN	Allergy and Infectious Diseases Research	000	4	3/16/2023	NON-COMPETING CONTINUATION	$135,000
														Subtotal = $135,000

Issue Date FY: 2022 ( Subtotal = $135,000 )
2022	2022	CHINA MEDICAL UNIVERSITY	NO.77, PUHE RD., SHENBEI NEW AREA	SHENYANG				CHN	Allergy and Infectious Diseases Research	000	3	5/20/2022	NON-COMPETING CONTINUATION	$135,000
														Subtotal = $135,000

Issue Date FY: 2021 ( Subtotal = $135,000 )
2021	2021	CHINA MEDICAL UNIVERSITY	NO.77, PUHE RD., SHENBEI NEW AREA	SHENYANG	LIAONING			CHN	Allergy and Infectious Diseases Research	000	2	4/8/2021	NON-COMPETING CONTINUATION	$135,000
														Subtotal = $135,000

Issue Date FY: 2020 ( Subtotal = $137,000 )
2020	2020	CHINA MEDICAL UNIVERSITY	NO.77, PUHE RD., SHENBEI NEW AREA	SHENYANG	LIAONING	110122		CHN	Allergy and Infectious Diseases Research	000	1	4/6/2020	NEW	$137,000
														Subtotal = $137,000

Grand Total All Awards = $677,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Antigen discovery for transmission-blocking vaccines in Plasmodium vivax

Award Number: R01AI150533

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/06/2020

PERIOD OF PERFORMANCE END DATE: 02/28/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer